Regeneron Pharmaceuticals anticipates recording a $56 million pre-tax acquired in-process research and development (IPR&D) charge in its Q3 2024 financial results. This charge stems from development milestone and up-front payments related to collaboration and licensing agreements, expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.43.The company notes that these preliminary Q3 2024 results remain subject to financial statement closing procedures and actual results may differ. The IPR&D charges may include research and development acquired through asset acquisitions, up-front payments, opt-in fees, development milestones, and premiums on equity securities related to collaboration agreements.

Regeneron Pharmaceuticals anticipates recording a $56 million pre-tax acquired in-process research and development (IPR&D) charge in its Q3 2024 financial results. This charge stems from development milestone and up-front payments related to collaboration and licensing agreements, expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.43.The company notes that these preliminary Q3 2024 results remain subject to financial statement closing procedures and actual results may differ. The IPR&D charges may include research and development acquired through asset acquisitions, up-front payments, opt-in fees, development milestones, and premiums on equity securities related to collaboration agreements.